

Statement on COVID-19

As a company focused on improving the health of people around the world, Ionis' priority during the COVID-19 pandemic is the safety of our employees, their families and the patients and healthcare workers who work with us and rely on our medicines.

Ionis is continuing to operate under guidance from national, state and local authorities and have implemented restrictions on travel and have established recommendations on social distancing, in line with recommendations from the Centers for Disease Control (CDC). Ionis is deemed a critical infrastructure company under the stay at home order that was issued by the Governor of California on March 19, 2020 and is maintaining its mission-critical activities. In order to keep employees safe, most of the Ionis workforce is working remotely and doing so efficiently.



I'm confident that the actions we are taking will help to protect the safety of patients, healthcare workers and employees, and better maintain the quality of our studies and their timelines. Our financial strength provides us with the ability to manage through this crisis and continue to execute on our strategic initiatives. Everyone at Ionis knows that sick people depend on us, and I'm encouraged by the strength, resilience and dedication of our employees, the patients we serve and all those who we work with on our patients' behalf in the face of this global pandemic. I believe that together we can overcome the challenges ahead to bring our life-changing medicines to patients as quickly as possible."

Brett P. Monia, Ph.D., Ionis' Chief Executive Officer

Ionis is well positioned from a financial perspective as a sustainably profitable company with \$2.5 billion in cash as of the end of December 2019. Our strong financial position is one of our many strengths and just one of the key factors that differentiates us from many other biotech companies. We are using this strength to continue investing in the priorities we believe have the greatest opportunity to generate value for patients and shareholders.

In the current environment, we continue to recognize the need to bring our medicines to patients as rapidly as possible while prioritizing the safety of our patients, healthcare providers and our employees. We have proactively identified potential risks and mitigation strategies to minimize any impacts on our operations. The current situation presents a number of potential risks, including those related to commercial products, supply chains, clinical trial operations and general business operations. Neither we nor our partners have seen significant impact on our commercial product or drug manufacturing supply chains. To date, we have experienced no significant delays in regulatory meetings, which are now being conducted virtually instead of in person.

We are continuously evaluating the impact to our clinical trial operations and have a task force in place that is meeting frequently to assess each program/situation individually and establishing mitigation actions/plans on an ongoing basis to minimize any impact to our clinical trials. Each study is different, so solutions vary from study to study. In addition to ensuring the safety of patients, healthcare workers and employees, we are focused on maintaining the quality of our studies and on meeting timelines.

KEY 
ACTIONS

Some of the actions we have already implemented or are in the process of implementing include:

- Switching to remote clinical site initiation and training via teleconferencing, videoconferencing and webcasts.
- Temporarily slowing or pausing enrollment in some of our studies to protect patients at risk for COVID-19 and to reduce the burden on our clinical sites dealing with the pandemic
- Monitoring remotely to keep our fully enrolled or nearly fully enrolled studies on track
- Continuing to screen patients in those studies for which enrollment is paused to identify patients who can quickly enter the study once enrollment starts again, which should help minimize impacts to study timelines
- Using home healthcare where possible